Fig. 1.

The exogenous addition of baricitinib decreases the in vitro IFN-γ response to SARS-CoV-2 peptides in COVID-19 patients. Baricitnib 10 nM or 1000 nM decreased the IFN-γ levels after stimulating whole-blood with spike- (A) or remainder-antigens-MPs (B) or SEB (C). IFN-γ was measured by ELISA in stimulated plasma. Statistical analysis was performed using the Wilcoxon test with Bonferroni correction, and p value was considered significant if ≤0.016. Number of patients analysed: A) n = 37; B) n = 36; C) n = 37. Footnotes: IFN: Interferon; SEB: Staphylococcal Enterotoxin B.